Smoking is associated with worse outcomes of COVID-19 particularly among younger adults: A systematic review and meta-analysis

Roengrudee Patanavanich, Stanton A. Glantz
doi: https://doi.org/10.1101/2020.09.22.20199802

Abstract

Background Smoking impairs lung immune functions and damages upper airways, increasing risks of contracting and severity of infectious diseases.

Methods We searched PubMed and Embase for studies published from January 1-May 25, 2020. We included studies reporting smoking behavior of COVID-19 patients and progression of disease, including death. We used a random effects meta-analysis and used meta-regression and lowess regressions to examine relationships in the data.

Results We identified 47 peer-reviewed papers with a total of 31,871 COVID-19 patients, 5,759 (18.1%) experienced disease progression and 5,734 (18.0%) with a history of smoking. Among smokers, 29.2% experienced disease progression, compared with 21.1% of non-smokers. The meta-analysis confirmed an association between smoking and COVID-19 progression (OR 1.56, 95% CI 1.32-1.83, p=0.001). Smoking was associated with increased risk of death from COVID-19 (OR 1.19, 95% CI 1.05-1.34, p=0.007). We found no significant difference (p=0.432) between the effects of smoking on COVID-19 disease progression between adjusted and unadjusted analyses, suggesting that smoking is an independent risk factor for COVID-19 disease progression. We also found the risk of having COVID-19 progression among younger adults (p=0.023), with the effect most pronounced among people under about 45 years old.

Conclusions Smoking is an independent risk for having severe progression of COVID-19, including mortality. The effects seem to be higher among young people. Smoking prevention and cessation should remain a priority for the public, physicians, and public health professionals during the COVID-19 pandemic.

BACKGROUND

Coronavirus disease 2019 (COVID-19) first occurred in Wuhan, China in December 2019 and has spread rapidly around the world. As of June 2020, the virus had infected over 6 million people and caused more than 300,000 deaths. Old people and those with pre-existing medical conditions including respiratory disease, hypertension, diabetes, cardiovascular disease, and cancer are more vulnerable to becoming critically ill when infected [1].

Smoking appears to enhance the risk of COVID-19 by its biological effects and behaviors of smokers. Smoking impairs lung function and pulmonary immune function, compromising the body’s defense mechanisms against infections [2]. Smoking is also a well-established risk factor for chronic diseases that are linked to more severe COVID-19. The World Health Organization (WHO) has advised the public that smoking could increase the risk of contracting COVID-19 because the behavior of smokers involves contact of fingers with the lips and removal of the protective face masks to smoke [3].

Our recent meta-analysis of the 19 peer-reviewed papers found that smokers have double the odds of COVID-19 progression risk [4]. Some people argue that the association between underlying health conditions and risk factors such as smoking to the severity of COVID-19 is still unclear due to inadequate adjustment of confounding factors [5]. In addition, it is unclear whether the association between smoking and severity of COVID-19 varies by age. This paper updates and extends our previous meta-analysis [4] of 19 studies to add 28 additional studies, including 7 that provided adjusted odds ratios and compared the association between smoking and COVID-19 disease progression between unadjusted analyses with adjusted analyses to examine whether smoking is an independent risk factor. We also assessed the effect of age of patients and conducted a sub-analysis for the risk of smoking on the mortality of COVID-19.

METHODS

This study followed the Preferred Reporting in Systematic Reviews and Meta-Analyses (PRISMA) guidelines and is registered with PROSPERO (CRD42020186864).

Data source and search strategy

We conducted a systematic search using PubMed and Embase on May 25, 2020, with the search term: “((smoking) OR (characteristics) OR (risk factors) OR (retrospective*) OR (outcomes) OR (smoker*)) AND ((COVID-19) OR (COVID) OR (coronavirus) OR (sars cov-2) OR (sars cov 2))” for studies published between January 1, 2020 and May 25, 2020. A total of 2,600 studies were retrieved through PubMed and 1,962 studies through Embase.

Eligibility criteria

Eligible studies included published peer-reviewed observational studies, retrospective cohort studies, prospective cohort studies, cross-sectional studies, case series, and case reports that reported demographic characteristics, comorbidities specifically smoking status, clinical manifestations, and clinical or disease outcomes of COVID-19 patients on disease progression of COVID-19 to more severe or critical conditions or death. We included both inpatient and outpatient settings. We excluded studies that did not report smoking status and outcomes, studies of children, studies that included other coronavirus infection and not specifically to COVID-19, studies that the number of smokers was zero or omitted, and studies in which all patients had the same outcome. There were no language restrictions.

Study Selection and Data Extraction

One author (RP) extracted information for each study, screened the abstract or the full text, with questions resolved through discussion among both authors (Figure A1).

The exposure group for our analysis were those who had a history of smoking (current smokers or former smokers) and unexposed group was never smokers, non-smoker, or not having a smoking history. Outcomes were progression of COVID-19 to more severe or critical conditions or death. Definitions of smoking status and disease progression for each study are shown in Table A1.

Quality Assessment

We evaluated the quality of studies using a modification of the ACROBAT-NRSI[6] tool on 5 domains: study population, exposure measurement, outcome assessment, measurement of confounders, and adequate follow-up. Each one of these domains was scored from 0 (low risk of bias) to 2 (high risk of bias) and the average score of each study was computed and discussed among both authors (Additional file and Table A2). Studies with the average score higher than 1 were considered high risk and excluded in a sensitivity analysis.

Statistical analyses

Our meta-analyses were based on unadjusted odds ratios (OR) that were either reported in the studies or computed unadjusted OR and 95% confidence interval (CI) using the number of smokers (current and former) and never smokers with and without disease progression. We also did a sensitivity analysis to determine the results changed when the 5 studies with high risk of bias were excluded.

We performed subgroup analyses of (1) the studies that reported association of smoking on COVID-19 mortality and (2) the association of COVID-19 disease progression between current smokers and never smokers (i.e., excluding former smokers) using the studies that reported whether the patient was a current, former, or never smoker (as separate categories).

We also computed the pooled adjusted OR using the studies that reported adjusted OR and 95% CI and compared it with the pooled unadjusted OR.

The results of the included studies were performed with random-effect models using the Stata version 14.0 metan command and metabias command with Egger’s test for the presence of publication bias. We used metareg command (with dummy variables to account for the pairing of adjusted and unadjusted ORs) to determine whether the adjustment of OR affected the results. To examine the effects by age, we used lowess command to generate a nonparametric fit estimate of the relationship between odds of disease progression and mean age of each study. We also tested for a trend using metareg command with mean age of each study as a continuous variable.

RESULTS

Study characteristics

From the total of 4,562 studies we found from our search, 237 studies were considered retrospective cohorts, prospective cohorts, or case series that provided clinical and demographic characteristics of COVID-19 patients. From the 237 studies, 83 studies reported smoking status of the patients, but only 47 studies [7-53] reported smoking status and disease progression of COVID-19 that met our inclusion and exclusion criteria (Figure A1).

Of the 47 studies (Table S1), 33 [10-13, 17-21, 23, 26-29, 31, 35, 37-53] were from China, 8 [8, 9, 14, 16, 22, 25, 33, 34] from the US, 3 [15, 32, 36] from Italy, 1 [7] from the UK, 1 [24] from South Korea, and 1 [30] from 11 countries in Asia, Europe, and North America (China, Japan, South Korea, Turkey, Spain, Italy, Germany, France, UK, Canada, and US).

Eight studies [9, 11, 17, 26, 30, 34, 36, 49] assessed whether the patient was a current, former, or never smoker (as separate categories), 15 [12, 14, 16, 20, 31, 39-43, 45, 46, 50, 51, 53] studies assessed whether the patient was a “current smoker”, 24 [7, 8, 10, 13, 15, 18, 19, 21-25, 27-29, 32, 33, 35, 37, 38, 44, 47, 48, 52] studies assessed whether the patient had a “history of smoking” (current or former).

Clinical outcome was defined as death in 8 studies [11, 15, 25, 30, 32, 33, 44, 53], intensive care unit (ICU) admission or requirement of mechanical ventilation in 6 studies [7, 9, 14, 16, 20, 22], prolonged viral shredding in 2 studies [42, 43], severe or critical (respiratory distress with respiratory rate ≥ 30/min, or oxygen saturation ≤ 93% at rest, or oxygenation index ≤ 300 mmHg, based on the diagnostic and treatment guideline for SARS-CoV-2 issued by Chinese National Health Committee [54] or the American Thoracic Society guidelines [55] for community acquired pneumonia) in 18 studies, the primary composite end point (ICU admission, the use of mechanical ventilation, or death) in 2 studies [17, 46], abnormal chest imaging in 1 study [51], acute cardiac injury in 1 study [18], progression of disease to more severe status (including increasing oxygen supplement, pneumonia exacerbation, transferred to ICU, and sepsis) in 10 studies [12, 19, 23, 24, 29, 31, 33, 36, 37, 47].

There were 5 studies [7, 12, 14, 32, 38] with high risk of bias scores (Table S2).

Smoking and COVID-19 disease progression

A total of 31,871 COVID-19 patients are included in our meta-analysis, 5,759 of whom (18.1%) experienced disease progression and 5,734 (18.0%) with a history of smoking. Among smokers, 29.2% experienced disease progression, compared with 21.1% of non-smokers. The meta-analysis showed an association between smoking and COVID-19 progression (OR 1.56, 95% CI 1.32-1.83, p=0.001) (Figure 1). There was statistically significant moderate heterogeneity among the studies (I2=45.3%, p=0.001) and no evidence of publication bias (p=0.243).

Figure 1.
Figure 1.

Smoking and COVID-19 disease progression.

Smoking prevalence was significantly higher among patients with disease progression than those without disease progression (p=0.04 by paired t-test).

Smoking and COVID-19 mortality

Eight studies [11, 15, 25, 30, 32, 33, 44, 53] (n = 13,272) reported death as the outcome of COVID-19 patients. The meta-analysis showed an association between smoking and COVID-19 mortality (OR 1.19, 95% CI 1.05-1.34, p=0.007; Figure S3). There was no evidence of heterogeneity among the studies (I2=0%, p=0.654) and no evidence of publication bias (p=0.632).

Studies of current smokers vs. never smokers

The 8 studies [9, 11, 17, 26, 30, 34, 36, 49] that reported current smokers vs. never smokers yielded an elevated point estimate for the effect of smoking on COVID-19 progression (OR 1.42, 95% CI 0.96-2.1, p=0.079; Figure A4), but it did not reach conventional statistical significance. There was statistically significant moderate heterogeneity (I2=58.6%, p=0.018) and no evidence of publication bias (p=0.390).

Unadjusted vs. Adjusted analyses

Seven studies [19, 25, 29, 30, 33, 34, 47] reported adjusted ORs. The point estimate for the adjusted ORs (OR 1.84, 95% CI 1.17-2.90, p=0.008; Figure A5, top) was higher than the point estimate for unadjusted ORs (OR 1.60, 95% CI 1.17-2.20, p=0.003; Figure A5, bottom), but this difference was not significant (p=0.432). For the adjusted ORs, the heterogeneity among the studies was high and statistically significant (I2=80.9%, p=0.001) with an evidence of publication bias (p=0.031). For the unadjusted ORs, the heterogeneity among the studies was moderate and statistically significant (I2=67.5%, p=0.003) with an evidence of publication bias (p=0.016).

Association between smoking and COVID-19 disease progression by age

The odds of COVID-19 disease progression between smokers and non-smokers dropped as the patients’ mean age increased across studies, with the drop most pronounced for studies where the mean age was less than about 45 years old (Figure 2). A meta-regression of the odds of COVID-19 disease progression between smokers and non-smokers and the patients’ mean age showed that each the odds of disease progression dropped statistically significantly by a factor of 0.82 (95% CI 0.69-0.97, p =0.023) per 10 years.

Figure 2.
Figure 2.

As the mean age of patients in a study falls the odds of COVID-19 progression increases. Solid line fit using a lowess regession.

Sensitivity analysis

Dropping the 5 studies [7, 12, 14, 32, 38] with high risk of bias scores had little effect on the odds of COVID-19 disease progression (OR 1.57, 95% CI 1.32-1.86, p=0.001; Figure S2). The heterogeneity among the studies was moderate and statistically significant (I2=50.6%, p=0.001) and there was no evidence of publication bias (p=0.169).

DISCUSSION

With more than twice as many studies available compared to our earlier meta-analysis [4], smoking remains a risk factor for COVID-19 disease progression, with smokers having 1.56 times the odds of progression in COVID-19 severity than non-smokers (Figure 1). The risk of smoking on COVID-19 disease progression was not changed significantly by adjusting for confounders, which suggests that smoking is an independent risk of COVID-19 progression. We also find that smokers are at increased risk of death from COVID-19 (Figure A3). These findings are not surprising because the well-established evidence that smoking is associated with a higher risk of viral infection [2]. In the past pandemics such as influenza [2] and Cov-MERS [56] smoking is also among leading risk factors for worse outcomes.

Young smokers appear to have a higher risk of COVID-19 disease progression than older smokers (Figure 2). A recent study also found that young adults are more medically vulnerable to severe COVID-19 illness if they are smokers [57]. The greater effect of smoking among young people is particularly important because in the U.S., almost 40% of COVID-19 patients are aged 18-44 years [58], and in China, 44% of COVID-19 patients are adults aged 20-49 years [59]. Even so, younger adults tend to perceiving lesser infection-fatality risks of COVID-19 [60] so that they are less likely to protect themselves from the infection. Our finding is consistent with a recent meta-analysis study [61] which concluded that age was negatively significantly associated with the effect of smoking on COVID-19 disease severity.

While there is not yet direct peer reviewed evidence of the effect of e-cigarette use on COVID-19 risk, the fact that e-cigarettes have similar adverse effects on pulmonary immune function [62] combined with the fact that e-cigarette use is concentrated among younger people, raises concerns and points to the need to collect data on e-cigarette use and COVID-19 risk.

Some have argued that smoking has a protective effect against COVID-19 because of the low prevalence of reported among COVID patients [63-65]. This is not new. There was also rumors that smoking protected patients from developing Cov-SARS during the 2003 pandemic [66]. However, a case-control study of 447 patients showed that smoking did not protect patients from contracting Cov-SARS after adjusting for confounding by age, gender, contact history, and occupation [66].

Reported smoking prevalence in the 33 studies in China ranged from 1.4% to 29.8% (median = 7.3%), which was substantially lower than 27.7% (52.1% for men and 2.7% for women) smoking prevalence in 2015 [67]. Four studies [9, 14, 16, 34] in the U.S. that reported the smoking prevalence among current smokers ranged from 1.3% to 33.3% (median=5.2%), which was also lower than 13.7% (15.6% for men and 12.0% for women) smoking prevalence in 2018 [68]. The other 4 studies [8, 22, 25, 33] in the U.S. reported the ever-smoking prevalence ranged from 13.3%-33.5%, which was also lower than 41.9% (47.2% for men and 37.3% for women) in 2017 [69]. One study [36] in Italy reported the smoking prevalence among current smokers of 3.2%, which was also substantial lower than 21.1% (26% for men and 17.2% for women) in 2016 [70]. The remaining studies that reported the ever-smoking prevalence (2 studies[15, 32] in Italy, 1 study [7] in UK and 1 study [24] in South Korea) were also lower than the countries’ rates (Italy: 16.7%-30% vs.43.9% (50% for men and 38.3% for women) in 2010 [71]; UK: 16.7% vs. 40.2 (44.3% for men and 36.5% for women) in 2018 [72]; South Korea: 18.5% vs.39.1% (81.6% for men and 6.9% for women) in 2015 [73]). These low levels of reported smoking among COVID-19 patients may reflect the difficulty of obtaining accurate smoking histories among seriously ill patients, especially when most medical facilities are operating at or above normal capacity. Despite the fact that the reported levels of smoking have been below population prevalences; however, the reported smoking prevalence among people with worse outcomes was significantly higher than those with less severe outcomes (13.5% vs. 9.7%, p=0.042).

Limitations

The studies used a variety of clinical definitions of disease progression and smoking status (Table A1). The varying definitions of disease progression include severity of disease based on clinical manifestations, development to more severe conditions, increasing oxygen supplements, prolonged viral shredding, organ injuries, ICU admission, and death. These varying definitions likely introduced increased variance in the results.

Moreover, smoking was significantly associated with death – a clearly defined endpoint – in the 8 studies [11, 15, 25, 30, 32, 33, 44, 53] that used this endpoint.

Most studies reported smoking status as having a smoking history which was unclear how they categorized former smokers. Of the 47 studies we reviewed, only 8 [9, 11, 17, 26, 30, 34, 36, 49] reported all three smoking categories (current, former, and never smokers). A meta-analysis of these studies found that current smoking was associated with a similar increase in the point estimate for the odds of disease progression (OR 1.42, 95% CI 0.96-2.1; Figure A4) as the other studies (OR 1.49, 95% CI 1.21-1.84), but the odds for current smoking did not reach conventional statistical significance (p=0.079).

Studies that only describe patient smoking history as “smoking history” or “history of smoking” do not provide enough information to analyze smoking as a risk factor given the fact that time since quitting could have significant influence on the patient’s outcomes.

All these limitations add to misclassification errors, which tend to bias results toward the null, suggest that this analysis underestimates the risk of smoking in terms of increasing COVID-19 severity.

The effects of smoking on COVID-19 disease progression by age reported in our paper is limited to the mean age of the studies. Individual level data on smoking, age, e-cigarette use, demographics and other risk factors are needed to perform a more sophisticated analysis. In addition, most of the studies were retrospective cohorts or case series, there might be recall bias, and could not conclude a causal relationship. Most of the meta-analyses in this study had moderate and statistically significant heterogeneity; the reliability of the meta-analysis might be compromised.

Conclusions

Smoking is an independent risk associated with severe progression of COVID-19, including mortality. The effects seem to be prominent among younger adults. Smoking prevention and cessation should remain a priority for the public, physicians, and public health professionals during the COVID-19 pandemic.

Data Availability

All data used to prepare this paper are available from the cited sources.

Authors’ contributions

RP developed the idea for the study, collected, analyzed the data, and wrote the first draft of the manuscript. SAG assisted with revising and refining the manuscript.

Funding

This work was supported by National Institute of Drug Abuse grant R01DA043950, cooperative agreement U54HL147127 from the National Heart, Lung, and Blood Institute and the Food and Drug Administration Center for Tobacco Products and the Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand. The content is solely the responsibility of the authors and does not necessarily represent the official views of NIH or the Food and Drug Administration. The funding sources for this study had no role in the study design, data collection, data analysis, data interpretation, or the writing of the manuscript.

Availability of data and materials

All data used to prepare this paper are available from the cited sources.

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Competing interests

The authors declare that there are no competing interests.

ADDITIONAL FILE

Risk of Bias Assessment

We evaluated the quality of studies using a modification of the ACROBAT-NRSI[6] tool on 5 domains: study population, exposure measurement, outcome assessment, measurement of confounders, and adequate follow-up. Each one of these domains was scored 0 for low risk of bias, 1 for moderate risk of bias, and 2 for high risk of bias and the average score of each study was computed and discussed among both authors. Studies with the average score higher than 1 were considered high risk and excluded in a sensitivity analysis.

Study population

  • Low risk: studies included at least 50 patients

  • Moderate risk: studies included at least 20 patients

  • High risk: studies included less than 20 patients

Exposure measurement

  • Low risk: studies reported 3 categories of smoking status: current, former, and never smokers

  • Moderate risk: studies reported 2 categories of smoking status

  • High risk: studies reported only 1 category of smoking status

Outcome assessment

  • Low risk: studies reported a clear definition of outcomes

  • High risk: studies did not report specific outcomes

Measurement of confounders

  • Low risk: adjustment for confounders

  • High risk: unadjusted analyses

Adequate follow-up

  • Low risk: identify duration of data collection

  • High risk: duration of data collection is unclear

References

References are the same as cited in the main text.

View this table:
Table A1.

Summary of Studies

View this table:
Table A2. Risk of Bias of Studies

(2=high risk, 1=intermediate risk, 0=low risk)

Figure A1.
Figure A1.

PRISMA diagram

Figure A2.
Figure A2.

Smoking and COVID-19 disease progression, dropping 5 studies with high risk of bias scores.

Figure A3.
Figure A3.

Smoking and COVID-19 mortality

Figure A4.
Figure A4.

Current smokers vs. never smokers and COVID-19 disease progression.

Figure A5.
Figure A5.

Smoking and disease progression in models that adjusted (top) and did not adjust (bottom) ORs for confounding variables.

Acknowledgement

Not applicable

Abbreviations

COVID-19
Coronavirus disease 2019
CI
Confidence Interval
OR
Odds ratios
ICU
Intensive care unit

REFRENCES

  1. 1.↵
    Coronavirus Disease 2019 (COVID-19): People Who Are at Higher Risk for Severe Illness [https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-at-higher-risk.html]
  2. 2.↵
    Arcavi L, Benowitz NL: Cigarette smoking and infection. Arch Intern Med 2004, 164(20):2206–2216..
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
  4. 4.↵
    Patanavanich R, Glantz SA: Smoking Is Associated With COVID-19 Progression: A Meta-analysis. Nicotine & Tobacco Research 2020.
  5. 5.↵
    Jordan RE, Adab P, Cheng KK: Covid-19: risk factors for severe disease and death. BMJ 2020, 368:m1198.
    OpenUrlFREE Full Text
  6. 6.↵
    A Cochrane Risk Of Bias Assessment Tool: for Non-Randomized Studies of Interventions (ACROBAT-NRSI), Version 1.0.0 [https://www.bristol.ac.uk/population-health-sciences/centres/cresyda/barr/riskofbias/robins-i/acrobat-nrsi/]
  7. 7.↵
    Beyrouti R, Adams ME, Benjamin L, Cohen H, Farmer SF, Goh YY, Humphries F, Jäger HR, Losseff NA, Perry RJ et al: Characteristics of ischaemic stroke associated with COVID-19. Journal of Neurology, Neurosurgery & Psychiatry 2020:jnnp-2020-323586.
  8. 8.↵
    Buckner FS, McCulloch DJ, Atluri V, Blain M, McGuffin SA, Nalla AK, Huang M-L, Greninger AL, Jerome KR, Cohen SA et al: Clinical Features and Outcomes of 105 Hospitalized patients with COVID-19 in Seattle, Washington. Clinical Infectious Diseases 2020.
  9. 9.↵
    CDC COVID-19 Response Team: Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 -United States, February 12-March 28, 2020. MMWR Morb Mortal Wkly Rep 2020, 69(13):382–386. doi: 310.15585/mmwr.mm16913e15582.
    OpenUrlCrossRefPubMed
  10. 10.↵
    Chen Q, Zheng Z, Zhang C, Zhang X, Wu H, Wang J, Wang S, Zheng C: Clinical characteristics of 145 patients with corona virus disease 2019 (COVID-19) in Taizhou, Zhejiang, China. Infection 2020:1–9.
  11. 11.↵
    Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, Ma K, Xu D, Yu H, Wang H et al: Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020, 368:m1091.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    Dong X, Cao YY, Lu XX, Zhang JJ, D. H, Yan YQ, Akdis CA, Gao YD: Eleven Faces of Coronavirus Disease 2019. Allergy 2020.
  13. 13.↵
    Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, Xiong W, Yang D, Chen R, Lu F et al: COVID-19 with Different Severity: A Multi-center Study of Clinical Features. Am J Respir Crit Care Med 2020.
  14. 14.↵
    Gayam V, Konala VM, Naramala S, Garlapati PR, Merghani MA, Regmi N, Balla M, Adapa S: Presenting characteristics, comorbidities, and outcomes of patients coinfected with COVID-19 and Mycoplasma pneumoniae in the USA. Journal of Medical Virology, n/a(n/a).
  15. 15.↵
    Giacomelli A, Ridolfo AL, Milazzo L, Oreni L, Bernacchia D, Siano M, Bonazzetti C, Covizzi A, Schiuma M, Passerini M et al: 30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: a prospective cohort study. Pharmacol Res 2020:104931.
  16. 16.↵
    Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, Satlin MJ, Campion TR, Jr.., Nahid M, Ringel JB et al: Clinical Characteristics of Covid-19 in New York City. N Engl J Med 2020.
  17. 17.↵
    Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC et al: Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020.
  18. 18.↵
    Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, Wang H, Wan J, Wang X, Lu Z: Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol 2020.
  19. 19.↵
    Hu L, Chen S, Fu Y, Gao Z, Long H, Wang JM, Ren HW, Zuo Y, Li H, Wang J et al: Risk Factors Associated with Clinical Outcomes in 323 COVID-19 Hospitalized Patients in Wuhan, China. Clin Infect Dis 2020.
  20. 20.↵
    Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X et al: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020, 395(10223):497–506..
    OpenUrlCrossRefPubMed
  21. 21.↵
    Huang R, Zhu L, Xue L, Liu L, Yan X, Wang J, Zhang B, Xu T, Ji F, Zhao Y et al: Clinical findings of patients with coronavirus disease 2019 in Jiangsu province, China: A retrospective, multi-center study. PLoS Negl Trop Dis 2020, 14(5):e0008280.
    OpenUrlCrossRefPubMed
  22. 22.↵
    Hur K, Price CPE, Gray EL, Gulati RK, Maksimoski M, Racette SD, Schneider AL, Khanwalkar AR: Factors Associated With Intubation and Prolonged Intubation in Hospitalized Patients With COVID-19. Otolaryngol Head Neck Surg 2020:194599820929640.
  23. 23.↵
    Ji D, Zhang D, Xu J, Chen Z, Yang T, Zhao P, Chen G, Cheng G, Wang Y, Bi J et al: Prediction for Progression Risk in Patients with COVID-19 Pneumonia: the CALL Score. Clinical Infectious Diseases 2020.
  24. 24.↵
    Kim ES, Chin BS, Kang CK, Kim NJ, Kang YM, Choi JP, Oh DH, Kim JH, Koh B, Kim SE et al: Clinical Course and Outcomes of Patients with Severe Acute Respiratory Syndrome Coronavirus 2 Infection: a Preliminary Report of the First 28 Patients from the Korean Cohort Study on COVID-19. J Korean Med Sci 2020, 35(13):e142
    OpenUrlCrossRefPubMed
  25. 25.↵
    Klang E, Kassim G, Soffer S, Freeman R, Levin MA, Reich DL: Morbid Obesity as an Independent Risk Factor for COVID-19 Mortality in Hospitalized Patients Younger than 50. Obesity, n/a(n/a).
  26. 26.↵
    Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, Shi J, Zhou M, Wu B, Yang Z et al: Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 2020.
  27. 27.↵
    Li YK, Peng S, Li LQ, Wang Q, Ping W, Zhang N, Fu XN: Clinical and Transmission Characteristics of Covid-19 - A Retrospective Study of 25 Cases from a Single Thoracic Surgery Department. Curr Med Sci 2020, 40(2):295–300.
    OpenUrl
  28. 28.
    Liang W, Liang H, Ou L, Chen B, Chen A, Li C, Li Y, Guan W, Sang L, Lu J et al: Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19. JAMA Internal Medicine 2020.
  29. 29.↵
    Liu W, Tao ZW, Lei W, Ming-Li Y, Kui L, Ling Z, Shuang W, Yan D, Jing L, Liu HG et al: Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J (Engl) 2020.
  30. 30.↵
    Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN: Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N Engl J Med 2020.
  31. 31.↵
    Mo P, Xing Y, Xiao Y, Deng L, Zhao Q, Wang H, Xiong Y, Cheng Z, Gao S, Liang K et al: Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin Infect Dis 2020.
  32. 32.↵
    Morassi M, Bagatto D, Cobelli M, D’Agostini S, Gigli GL, Bnà C, Vogrig A: Stroke in patients with SARS-CoV-2 infection: case series. Journal of Neurology 2020.
  33. 33.↵
    Palaiodimos L, Kokkinidis DG, Li W, Karamanis D, Ognibene J, Arora S, Southern WN, Mantzoros CS: Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York. Metabolism 2020, 108:154262.
    OpenUrlCrossRefPubMed
  34. 34.↵
    Petrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell L, Chernyak Y, Tobin KA, Cerfolio RJ, Francois F, Horwitz LI: Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. Bmj 2020, 369:m1966.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W et al: Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis 2020.
  36. 36.↵
    Rastrelli G, Di Stasi V, Inglese F, Beccaria M, Garuti M, Di Costanzo D, Spreafico F, Greco GF, Cervi G, Pecoriello A et al: Low testosterone levels predict clinical adverse outcomes in SARS-CoV-2 pneumonia patients. Andrology, n/a(n/a).
  37. 37.↵
    Ren D, Ren C, Yao RQ, Feng YW, Yao YM: Clinical features and development of sepsis in patients infected with SARS-CoV-2: a retrospective analysis of 150 cases outside Wuhan, China. Intensive Care Med 2020:1–4.
  38. 38.↵
    Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J: Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan. Crit Care 2020, 24(1):108..
    OpenUrlCrossRefPubMed
  39. 39.↵
    Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y, Lang C, Huang D, Sun Q, Xiong Y et al: Clinical Features and Treatment of COVID-19 Patients in Northeast Chongqing. J Med Virol 2020.
  40. 40.
    Wang R, Pan M, Zhang X, Fan X, Han M, Zhao F, Miao M, Xu J, Guan M, Deng X et al: Epidemiological and clinical features of 125 Hospitalized Patients with COVID-19 in Fuyang, Anhui, China. Int J Infect Dis 2020.
  41. 41.
    Xiong F, Tang H, Liu L, Tu C, Tian JB, Lei CT, Liu J, Dong JW, Chen WL, Wang XH et al: Clinical Characteristics of and Medical Interventions for COVID-19 in Hemodialysis Patients in Wuhan, China. J Am Soc Nephrol 2020.
  42. 42.↵
    Xu K, Chen Y, Yuan J, Yi P, Ding C, Wu W, Li Y, Ni Q, Zou R, Li X et al: Factors associated with prolonged viral RNA shedding in patients with COVID-19. Clin Infect Dis 2020.
  43. 43.↵
    Yan D, Liu XY, Zhu YN, Huang L, Dan BT, Zhang GJ, Gao YH: Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection. Eur Respir J 2020.
  44. 44.↵
    Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M et al: Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020.
  45. 45.↵
    Yao Q, Wang P, Wang X, Qie G, Meng M, Tong X, Bai X, Ding M, Liu W, Liu K et al: Retrospective study of risk factors for severe SARS-Cov-2 infections in hospitalized adult patients. Pol Arch Intern Med 2020.
  46. 46.↵
    Yu Q, Wang Y, Huang S, Liu S, Zhou Z, Zhang S, Zhao Z, Yu Y, Yang Y, Ju S: Multicenter cohort study demonstrates more consolidation in upper lungs on initial CT increases the risk of adverse clinical outcome in COVID-19 patients. Theranostics 2020, 10(12):5641–5648.
    OpenUrlCrossRef
  47. 47.↵
    Yu T, Cai S, Zheng Z, Cai X, Liu Y, Yin S, Peng J, Xu X: Association Between Clinical Manifestations and Prognosis in Patients with COVID-19. Clin Ther 2020.
  48. 48.↵
    Yu X, Sun X, Cui P, Pan H, Lin S, Han R, Jiang C, Fang Q, Kong D, Zhu Y et al: Epidemiological and clinical characteristics of 333 confirmed cases with coronavirus disease 2019 in Shanghai, China. Transbound Emerg Dis 2020.
  49. 49.↵
    Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, Akdis CA, Gao YD: Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020.
  50. 50.↵
    Zhang R, Ouyang H, Fu L, Wang S, Han J, Huang K, Jia M, Song Q, Fu Z: CT features of SARS-CoV-2 pneumonia according to clinical presentation: a retrospective analysis of 120 consecutive patients from Wuhan city. Eur Radiol 2020:1-10.
  51. 51.↵
    Zhang X, Cai H, Hu J, Lian J, Gu J, Zhang S, Ye C, Lu Y, Jin C, Yu G et al: Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings. Int J Infect Dis 2020, 94:81–87.
    OpenUrlCrossRefPubMed
  52. 52.↵
    Zheng Y, Xiong C, Liu Y, Qian X, Tang Y, Liu L, Leung EL, Wang M: Epidemiological and clinical characteristics analysis of COVID-19 in the surrounding areas of Wuhan, Hubei Province in 2020. Pharmacol Res 2020, 157:104821.
    OpenUrlCrossRef
  53. 53.↵
    Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X et al: Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020.
  54. 54.↵
    Diagnosis and Treatment Protocol for COVID-19 [http://en.nhc.gov.cn/2020-03/29/c_78469.htm]
  55. 55.↵
    Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, Cooley LA, Dean NC, Fine MJ, Flanders SA et al: Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 2019, 200(7):e45–e67.
    OpenUrlCrossRefPubMed
  56. 56.↵
    Park JE, Jung S, Kim A, Park JE: MERS transmission and risk factors: a systematic review. BMC Public Health 2018, 18(1):574..
    OpenUrlCrossRefPubMed
  57. 57.↵
    Adams SH, Park MJ, Schaub JP, Brindis CD, Irwin CE: Medical Vulnerability of Young Adults to Severe COVID-19 Illness—Data From the National Health Interview Survey. Journal of Adolescent Health 2020.
  58. 58.↵
    Coronavirus Disease 2019 (COVID-19): Cases in the U.S.[https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html]
  59. 59.↵
    The Novel Coronavirus Pneumonia Emergency Response Epidemiology T: The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020. 2020, 2(8):113–122.
    OpenUrl
  60. 60.↵
    Bruine de Bruin W: Age differences in COVID-19 risk perceptions and mental health:Evidence from a national US survey conducted in March 2020. The Journals of Gerontology: Series B 2020.
  61. 61.↵
    Karanasos A, Aznaouridis K, Latsios G, Synetos A, Plitaria S, Tousoulis D, Toutouzas K: Impact of smoking status on disease severity and mortality of hospitalized patients with COVID-19 infection: a systematic review and meta-analysis. Nicotine & Tobacco Research 2020.
  62. 62.↵
    Gotts JE, Jordt SE, McConnell R, Tarran R: What are the respiratory effects of e-cigarettes? BMJ 2019, 366:5275..
  63. 63.↵
    Fontanet A, Tondeur L, Madec Y, Grant R, Besombes C, Jolly N, Fernandes Pellerin S, Ungeheuer M-N, Cailleau I, Kuhmel L et al: Cluster of COVID-19 in northern France: A retrospective closed cohort study. medRxiv 2020:2020.2004.2018.20071134.
  64. 64.
    Farsalinos K, Barbouni A, Niaura R: Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option? Intern Emerg Med 2020:1–8.
  65. 65.↵
    Miyara M, Tubach F, Pourcher V, Morelot-Panzini C, Pernet J, Haroche J, Lebbah S, Morawiec E, Gorochov G, Caumes E et al: Low incidence of daily active tobacco smoking in patients with symptomatic COVID-19. Qeios 2020.
  66. 66.↵
    Rainer T, Smit D, Cameron P: Smoking and Severe Acute Respiratory Syndrome.Hong Kong Journal of Emergency Medicine 2004, 11(3):143–145.
    OpenUrlCrossRef
  67. 67.↵
    Parascandola M, Xiao L: Tobacco and the lung cancer epidemic in China.Translational Lung Cancer Research 2019:S21–S30..
  68. 68.↵
    Current Cigarette Smoking Among Adults in the United States[https://www.cdc.gov/tobacco/data_statistics/fact_sheets/adult_data/cig_smoking/index.htm]
  69. 69.↵
    State Cancer Profile: Screening and Risk Factors Table[https://statecancerprofiles.cancer.gov/data-topics/screening-risk-factors.html]
  70. 70.↵
    Lugo A, Zuccaro P, Pacifici R, Gorini G, Colombo P, La Vecchia C, Gallus S: Smoking in Italy in 2015-2016: prevalence, trends, roll-your-own cigarettes, and attitudes towards incoming regulations. Tumori 2017, 103(4):353–359.
    OpenUrl
  71. 71.↵
    Verlato G, Accordini S, Nguyen G, Marchetti P, Cazzoletti L, Ferrari M, Antonicelli L, Attena F, Bellisario V, Bono R et al: Socioeconomic inequalities in smoking habits are still increasing in Italy. BMC Public Health 2014, 14:879.
    OpenUrl
  72. 72.↵
  73. 73.↵
    Kim Y, Cho W-K: Effects of smoking on disease risk among South Korean adults.Tobacco induced diseases 2018, 16:45–45.
Back to top
Posted September 23, 2020.
Download PDF
Data/Code
Email
Smoking is associated with worse outcomes of COVID-19 particularly among younger adults: A systematic review and meta-analysis
Roengrudee Patanavanich, Stanton A. Glantz
medRxiv 2020.09.22.20199802; doi: https://doi.org/10.1101/2020.09.22.20199802
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area